HAVENS ADVISORS LLC recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
600 LEXINGTON AVE NEW YORK, NY 10022
As of the latest 13F report, the guru’s equity portfolio contained 31 stocks valued at a total of $39.00Mil. The top holdings were COWN(8.84%), UMPQ(6.84%), and TSEM(6.64%).
According to GuruFocus data, these were HAVENS ADVISORS LLC’s top five trades of the quarter.
Rentokil Initial PLC
The guru established a new position worth 81,000 shares in NYSE:RTO, giving the stock a 6.34% weight in the equity portfolio. Shares traded for an average price of $30.57 during the quarter.
On 01/25/2023, Rentokil Initial PLC traded for a price of $31.15 per share and a market cap of $15.70Bil. The stock has returned -10.64% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Rentokil Initial PLC has a price-earnings ratio of 33.79, a price-book ratio of 6.56, a price-earnings-to-growth (PEG) ratio of 8.89, a EV-to-Ebitda ratio of 20.32 and a price-sales ratio of 3.06.
The price-to-GF Value ratio is 0.75, earning the stock a GF Value rank of 9.
Horizon Therapeutics PLC
The guru established a new position worth 21,000 shares in NAS:HZNP, giving the stock a 6.07% weight in the equity portfolio. Shares traded for an average price of $83.06 during the quarter.
On 01/25/2023, Horizon Therapeutics PLC traded for a price of $113.05 per share and a market cap of $25.82Bil. The stock has returned 30.53% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, Horizon Therapeutics PLC has a price-earnings ratio of 46.33, a price-book ratio of 5.14, a EV-to-Ebitda ratio of 24.71 and a price-sales ratio of 7.21.
The price-to-GF Value ratio is 0.90, earning the stock a GF Value rank of 7.
ChemoCentryx Inc
The guru sold out of their 75,000-share investment in NAS:CCXI. Previously, the stock had a 5.88% weight in the equity portfolio. Shares traded for an average price of $51.92 during the quarter.
On 01/25/2023, ChemoCentryx Inc traded for a price of $51.99 per share and a market cap of $3.74Bil. The stock has returned 49.18% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, ChemoCentryx Inc has a price-book ratio of 15.68, a EV-to-Ebitda ratio of -27.52 and a price-sales ratio of 98.47.
The price-to-GF Value ratio is 1.04, earning the stock a GF Value rank of 5.
Terminix Global Holdings Inc
The guru sold out of their 99,200-share investment in NYSE:TMX. Previously, the stock had a 5.77% weight in the equity portfolio. Shares traded for an average price of $38.97 during the quarter.
On 01/25/2023, Terminix Global Holdings Inc traded for a price of $37.87 per share and a market cap of $4.60Bil. The stock has returned -5.51% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, Terminix Global Holdings Inc has a price-earnings ratio of 71.45, a price-book ratio of 1.89, a price-earnings-to-growth (PEG) ratio of 3.40, a EV-to-Ebitda ratio of 18.89 and a price-sales ratio of 2.21.
The price-to-GF Value ratio is 0.76, earning the stock a GF Value rank of 9.
Alleghany Corp
The guru sold out of their 4,400-share investment in NYSE:Y. Previously, the stock had a 5.61% weight in the equity portfolio. Shares traded for an average price of $843.86 during the quarter.
On 01/25/2023, Alleghany Corp traded for a price of $847.79 per share and a market cap of $11.41Bil. The stock has returned 27.62% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 7 out of 10.
In terms of valuation, Alleghany Corp has a price-earnings ratio of 33.43, a price-book ratio of 1.44, a price-earnings-to-growth (PEG) ratio of 1.49, a EV-to-Ebitda ratio of 13.62 and a price-sales ratio of 0.99.
The price-to-GF Value ratio is 0.96, earning the stock a GF Value rank of 5.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
